Has Yordy Brito Aguila received payments from drug or device companies?

Yes. Drug and device makers reported $15,807 in general payments to Yordy Brito Aguila across 730 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Yordy Brito Aguila did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Yordy Brito Aguila come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Yordy Brito Aguila

Family · Pembroke Pines, FLNPI 1033599246

Payments from drug & device makers

$15,807in general payments, 2019–2025

Across 730 payments — averaging $21.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$3K
Lilly USA, LLC$1K
AbbVie$1K
Amgen$1K
Pfizer$1K
Novo Nordisk$824
plus $7K from 43 others

What the payments were for

Food & beverage$15,807100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	92	$2,786
Lilly USA, LLC	78	$1,413
AbbVie	86	$1,406
Amgen(2 entities)	91	$1,207
Pfizer	48	$1,040
Novo Nordisk	39	$824
Insulet Corporation	38	$782
Boehringer Ingelheim	15	$670
Novartis	23	$577
Amarin Pharma, Inc.	32	$526
Biohaven Pharmaceuticals, Inc.	21	$451
Dexcom, Inc.	6	$387
Exact Sciences	14	$330
Johnson & Johnson	12	$321
Abbott	10	$284
Astellas Pharma US Inc	12	$270
Biohaven Pharmaceutical Holding Company Ltd.	11	$242
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	11	$218
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	5	$209
Bayer	9	$191
Sunovion Pharmaceuticals Inc.	7	$154
Verity Pharmaceuticals Inc.	5	$129
Esperion Therapeutics, Inc.	7	$120
Indivior Inc.	4	$99
Gilead	4	$99
GSK	4	$86
Mannkind Corporation	3	$86
Shield Therapeutics Inc	5	$85
Intra-sana Laboratories	3	$85
Janssen Scientific Affairs, LLC	3	$85
Sanofi-aventis U.S. LLC	4	$69
Mallinckrodt Hospital Products Inc.	3	$65
Cvrx, Inc.	3	$54
Acerus Pharmaceuticals Corporation	2	$50
Hologic Sales And Service, LLC	2	$49
Corcept Therapeutics	2	$49
IBSA Pharma Inc.	2	$38
Phadia US Inc.	2	$37
Kowa Pharmaceuticals America, Inc.	2	$34
Mylan Specialty L.p.	1	$32
Sumitomo Pharma America, Inc.	1	$22
Ironwood Pharmaceuticals, Inc	1	$22
Tolmar, Inc.	1	$21
Alkermes, Inc.	1	$21
Phathom Pharmaceuticals, Inc.	1	$21
Merck	1	$19
Cequr Corporation	1	$16
Orexo US, Inc.	1	$15
Hikma Pharmaceuticals USA	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,807 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
FarxigaDapagliflozin Propanediol	90	$89,125
MounjaroTirzepatide	71	$76,831
OzempicSemaglutide	42	$66,512
JardianceEmpagliflozin	41	$48,788
Repatha SureclickEvolocumab	29	$31,445
Tresiba Flextouch U-100Insulin Degludec	33	$29,509
EliquisApixaban	21	$26,147
LinzessLinaclotide	26	$17,054
Breztri AerosphereBudesonide/Glycopyr/Formoterol	21	$13,214
Synjardy XrEmpagliflozin/Metformin Hcl	14	$12,271
MyrbetriqMirabegron	16	$9,679
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	12	$7,623
Fluticasone-SalmeterolFluticasone Propion/Salmeterol	16	$3,362
Lantus SolostarInsulin Glargine,hum.Rec.Anlog	24	$3,087
Atorvastatin Calcium	244	$2,304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere	$2,786	$102,339111 claims
Lilly USA, LLCMounjaro	$1,413	$76,83171 claims
Novo NordiskOzempic	$824	$66,51242 claims
Boehringer IngelheimJardiance, Synjardy Xr	$670	$61,05955 claims
PfizerEliquis	$1,040	$26,14721 claims
AbbVieLinzess, Synthroid	$1,406	$18,49440 claims
Astellas Pharma US IncMyrbetriq	$270	$9,67916 claims
GSKTrelegy Ellipta	$86	$7,62312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Pembroke Pines

John HuffakerVenice$8M
Stephanie MompointMiami$4.5M
Miguel TrujilloMiami Gardens$4.4M
Itsel Cardenas RamonMiami$1M
Lewis HarringtonTampa$954K
Adam StrosbergFort Lauderdale$859K
Danielle PharesFt Lauderdale$713K
David RodriguezHialeah$658K
Donna OrtizOrlando$417K
Patrick SzarazMiami$327K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →